Evidence map›Paper›PMID 40682670›Full record

ArticleTechniques in coloproctology2025

Safety and feasibility of D3 lymph node dissection in oldest-old patients undergoing colorectal cancer surgery: a multi-institutional, retrospective analysis.

R Inada, F Teraishi, T Mitsuhashi, S Takanaga, T Toshima, T Ohtani, R Yoshida, N Hori, K Shigemitsu, S Yamamoto and 10 more

Abstract readMulticenter Study
In one paragraph

Article in Techniques in coloproctology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

R InadaDepartment of Surgery, Kochi Health Sciences Center, Kochi, Japan.
F TeraishiDepartment of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, 700-8558, Japan. pkc1940h@okayama-u.ac.jp.ORCID 0000-0001-5133-2644
T MitsuhashiCenter for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.
S TakanagaDepartment of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, 700-8558, Japan.
T ToshimaDepartment of Surgery, Kagawa Rosai Hospital, Marugame, Japan.
T OhtaniDepartment of Surgery, Saiseikai Okayama Hospital, Okayama, Japan.
R YoshidaDepartment of Surgery, Okayama Rosai Hospital, Okayama, Japan.
N HoriDepartment of Surgery, Tottori Municipal Hospital, Tottori, Japan.
K ShigemitsuDepartment of Surgery, Tsuyama Chuo Hospital, Tsuyama, Japan.
S YamamotoDepartment of Surgery, Okayama City Hospital, Okayama, Japan.
T KubotaDepartment of Surgery, Kobe Red Cross Hospital, Kobe, Japan.
Y OkanoDepartment of Surgery, Onomichi City Hospital, Onomichi, Japan.
T NobuhisaDepartment of Surgery, Himeji Red Cross Hospital, Himeji, Japan.
F TaniguchiDepartment of Surgery, National Hospital Organization Iwakuni Clinical Center, Iwakuni, Japan.
W IshikawaDepartment of Surgery, Fukuyama City Hospital, Fukuyama, Japan.
R ShojiDepartment of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, 700-8558, Japan.
T MatsudaDepartment of Surgery, Matsuda Hospital, Kurashiki, Japan.
T UmeokaDepartment of Surgery, Matsuyama City Hospital, Matsuyama, Japan.
T FujiwaraDepartment of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, 700-8558, Japan.
Setouchi Colorectal Neoplasm Registration Study Group Collaborators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundColorectal cancer (CRC) is a significant health burden, with lymph node dissection (LND) playing a critical role in staging and guiding treatment. However, the optimal extent of LND for the oldest-old population (aged ≥ 90 years) remains undefined because of insufficient targeted clinical data. This study aimed to compare the short-term outcomes of D3 versus non-D3 LND in Stage II-III CRC in oldest-old patients.

methodsThis retrospective cohort study utilized data from the Setouchi Colorectal Neoplasm Registration database, including 282 oldest-old patients with CRC treated between 2011 and 2022. Patients were stratified into D3 and non-D3 LND groups, with inverse-probability-weighted regression adjustment implemented to address potential confounding factors. Postoperative complications and hospital stays were analyzed using regression models and descriptive statistics.

resultsD3 LND resulted in significantly higher lymph node harvests in both Stage II and Stage III patients (p < 0.01). There were no significant differences in overall or major postoperative complications between D3 and non-D3 groups. Hospital stays were comparable for Stage II patients but shorter for Stage III patients in the D3 group (p < 0.01). Complication rates ranged from 28% to 47.7%, with surgical site infections and pneumonia being the most common.

conclusionsD3 LND can be safely performed in oldest-old patients with CRC without increasing postoperative complications or extending hospital stays. These findings support the feasibility of extensive LND in this age group, but further studies are needed to evaluate its oncological benefits.

Indexed as

Colorectal NeoplasmsLymph Node ExcisionAged, 80 and overAge FactorsFeasibility StudiesFemaleHumansLength of StayLymph NodesMaleNeoplasm StagingPostoperative ComplicationsRetrospective StudiesTreatment OutcomeColorectal cancerLymph node dissectionOldest-old patientsPostoperative complication

Identifiers

PMID40682670
PMCPMC12276142

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.